Asset parking
20 June 2017

A wave of consolidation and buyouts among drug outsourcers generated plenty of bids for latest target Parexel. The prospect for cost cuts ought to have given rival companies the upper hand. Yet private-equity shop Pamplona won by offering $4.5 bln, suggesting it paid too much.